Chemours Stock Recovery After Executives Suspension: BMO Downgrades to Underperform
Friday, 1 March 2024, 21:10
Chemours Stock Recovery After Executives Suspension
Chemours (CC) has seen a small rebound in its stock price after facing a significant decline triggered by the suspension of key executives due to an ongoing accounting investigation. The company is striving to regain market confidence amidst the challenging period.
BMO Downgrades Chemours to Underperform
BMO has recently downgraded Chemours to Underperform, signaling a less optimistic view on the stock's performance. The price target set at $19 indicates a cautious approach adopted by the financial institution in light of recent events.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.